<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04384523</url>
  </required_header>
  <id_info>
    <org_study_id>US-HY1001</org_study_id>
    <nct_id>NCT04384523</nct_id>
  </id_info>
  <brief_title>A Study of OsrHSA in Adult Healthy Male and Female Volunteers</brief_title>
  <official_title>A Phase 1 Randomized, Double Blinded, Placebo-Controlled Single Dose Escalation Study of OsrHSA in Adult Healthy Male and Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Healthgen Biotechnology Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Healthgen Biotechnology Corp.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1 randomized, double blinded, placebo-controlled single dose escalation study of&#xD;
      OsrHSA in adult healthy male and female volunteers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1 randomized, double blinded, placebo-controlled, single dose escalation&#xD;
      study to evaluate safety, tolerability, PK, and immunogenicity of OsrHSA in healthy&#xD;
      volunteers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 4, 2019</start_date>
  <completion_date type="Actual">July 13, 2020</completion_date>
  <primary_completion_date type="Actual">March 17, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This is a Phase 1 randomized, double blinded, placebo-controlled, single dose escalation study in healthy volunteers to evaluate safety, tolerability, PK, PD and immunogenicity of OsrHSA.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>from date of Informed Consent through Day 30 (Study Completion)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration [Cmax]</measure>
    <time_frame>pre-dose, 0.5 hours after dose initiating, EOI (End of Infusion), and 0.5 hours, 4 hours, 12 hours, 24 hours (Day 2), 48 hours (Day 3), Day 5, Day 8, Day 15, Day 22, and Day 30 post End of Infusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With ADA Incident Events</measure>
    <time_frame>pre-dose, Day 8, Day 15, Day 22, and Day 30 post End of Infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Ascites Hepatic</condition>
  <arm_group>
    <arm_group_label>OsrHSA 20 mg/kg IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>OsrHSA 40 mg/kg IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>OsrHSA 80 mg/kg IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>OsrHSA 140 mg/kg IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>OsrHSA 200 mg/kg IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OsrHSA 20 mg/kg IV</intervention_name>
    <description>A single dose of OsrHSA 20 mg/kg IV infusion at a rate lower than 2 ml/min</description>
    <arm_group_label>OsrHSA 20 mg/kg IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OsrHSA 40 mg/kg IV</intervention_name>
    <description>A single dose of OsrHSA 40 mg/kg IV infusion at a rate lower than 2 ml/min</description>
    <arm_group_label>OsrHSA 40 mg/kg IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OsrHSA 80 mg/kg IV</intervention_name>
    <description>A single dose of OsrHSA 80 mg/kg IV infusion at a rate lower than 2 ml/min</description>
    <arm_group_label>OsrHSA 80 mg/kg IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OsrHSA 140 mg/kg IV</intervention_name>
    <description>A single dose of OsrHSA 140 mg/kg IV infusion at a rate lower than 2 ml/min</description>
    <arm_group_label>OsrHSA 140 mg/kg IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OsrHSA 200 mg/kg IV</intervention_name>
    <description>A single dose of OsrHSA 200 mg/kg IV infusion at a rate lower than 2 ml/min</description>
    <arm_group_label>OsrHSA 200 mg/kg IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal Saline (0.9% Sodium Chloride)</description>
    <arm_group_label>OsrHSA 140 mg/kg IV</arm_group_label>
    <arm_group_label>OsrHSA 20 mg/kg IV</arm_group_label>
    <arm_group_label>OsrHSA 200 mg/kg IV</arm_group_label>
    <arm_group_label>OsrHSA 40 mg/kg IV</arm_group_label>
    <arm_group_label>OsrHSA 80 mg/kg IV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must meet all the following criteria to be enrolled in the trial&#xD;
&#xD;
          1. Able to understand and willing to sign the ICF&#xD;
&#xD;
          2. Healthy male and female subjects, 18-55 years of age, non-smokers, or subjects must&#xD;
             have been non-smoking for at least 3 months prior to their screening visit.&#xD;
&#xD;
          3. Has adequate venous access&#xD;
&#xD;
          4. With no significant medical history, and in good health as determined by detailed&#xD;
             medical history (neurological, endocrinal, cardiovascular, pulmonary, hematological,&#xD;
             immunologic, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease),&#xD;
             full physical examination,vital signs, 12-lead electrocardiogram (ECG), urinalysis and&#xD;
             laboratory tests at screening. For eligibility purposes, abnormal laboratory or vital&#xD;
             signs results may be repeated once if abnormal result is observed at the initial&#xD;
             reading. Moreover, abnormalities found in the ECG may need to be confirmed by repeated&#xD;
             measurements.&#xD;
&#xD;
          5. Subjects must have adequate organ function according to the following laboratory&#xD;
             values:&#xD;
&#xD;
               -  Bone marrow function (absolute neutrophil count ≥1500/mm3 and platelet count&#xD;
                  ≥100,000/mm3)&#xD;
&#xD;
               -  Adequate liver function [alanine aminotransferase (ALT) to ≤1.5× upper limit&#xD;
                  normal (ULN) and alkaline phosphatase to ≤1.5× ULN, total bilirubin ≤1.5 mg/dL]&#xD;
&#xD;
               -  Adequate renal function creatinine clearance ≥60 mL/min based on Cockcroft- Gault&#xD;
                  equation, or serum creatinine level ≤1.5 times the ULN.&#xD;
&#xD;
          6. Be a female of non-childbearing potential (i.e., physiologically incapable of becoming&#xD;
             pregnant, including any female who is 2 years post-menopausal and have an FSH &gt;&#xD;
             40mIU/mL, or surgically sterile [defined as having a bilateral oophorectomy,&#xD;
             hysterectomy or tubal ligation]) or agree to one of the following to prevent pregnancy&#xD;
             and, if a woman of childbearing potential, have a negative urine pregnancy test at&#xD;
             screening:&#xD;
&#xD;
               -  Practicing abstinence&#xD;
&#xD;
               -  If a sexually active woman of childbearing potential (sexually active with a&#xD;
                  non-sterile male partner) agrees to prevent pregnancy by using double methods of&#xD;
                  contraception as follow until at least 30 days after the administration of the&#xD;
                  investigational product:&#xD;
&#xD;
                    1. simultaneous use of intra-uterine contraceptive device, placed at least 4&#xD;
                       weeks prior to study drug administration, and condom for the male partner;&#xD;
&#xD;
                    2. simultaneous use of hormonal contraceptives, starting at least 4 weeks prior&#xD;
                       to study drug administration and must agree to use the same hormonal&#xD;
                       contraceptive throughout the study, and condom for the male partner;&#xD;
&#xD;
                    3. simultaneous use of diaphragm with intravaginally applied spermicide and&#xD;
                       male condom for the male partner, starting at least 21 days prior to study&#xD;
                       drug administration.&#xD;
&#xD;
               -  Male subjects who are not vasectomized for at least 6 months and who are sexually&#xD;
                  active with a non-sterile female partner must agree to use double methods of&#xD;
                  contraception below from the first dose of randomized study drug until 90 days&#xD;
                  after their dose and must not donate sperm during their study participation&#xD;
                  period:&#xD;
&#xD;
                    1. Simultaneous use of a male condom and, for the female partner, hormonal&#xD;
                       contraceptives (used since at least 4 weeks) or intra-uterine contraceptive&#xD;
                       device (placed since at least 4 weeks);&#xD;
&#xD;
                    2. Simultaneous use of a male condom and, for the female partner, a diaphragm&#xD;
                       with intravaginally applied spermicide.&#xD;
&#xD;
          7. Body mass index (BMI) 18-30 kg/m2 and body weight ≥ 50.0 kg for males and ≥ 45.0 kg&#xD;
             for females.&#xD;
&#xD;
          8. Blood pressure ≤ 139/89 mm Hg.&#xD;
&#xD;
          9. Subjects are able to follow the study protocol and complete the trial.&#xD;
&#xD;
         10. At least 25% of the enrolled subjects will be of Asian descent, defined as Chinese,&#xD;
             Japanese, Korean, Vietnamese, Hmong, and their offspring.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects who meet any of the following criteria cannot be enrolled:&#xD;
&#xD;
          1. History of severe infection within 4 weeks to dosing.&#xD;
&#xD;
          2. Signs and symptoms of any active infection regardless of severity within 2 weeks prior&#xD;
             to dosing.&#xD;
&#xD;
          3. Meals &amp; Dietary Restrictions: No seafood or high-fat food will be served during&#xD;
             confinement in the clinical center&#xD;
&#xD;
          4. Subjects who have any history of allergy to food or drug will be excluded ( Including&#xD;
             allergies, hypersensitivity, or intolerance to rice or rice products )&#xD;
&#xD;
          5. Use of any prescription drugs, herbal supplements, or nonprescription drugs including&#xD;
             oral anti-histamines (for seasonal allergies) within 1 month or 5 half-lives&#xD;
             (whichever is longer) prior to study drug administration, or dietary supplements&#xD;
             within 1 week prior to study drug administration, unless, in the opinion of the&#xD;
             Investigator and Sponsor, the medication will not interfere with the study.&#xD;
             Over-the-counter multivitamins will be permitted. If needed, paracetamol/acetaminophen&#xD;
             may be used, but must be documented in the Concomitant medications/Significant&#xD;
             non-drug therapies page of the source data. Any questions of concomitant medications&#xD;
             should be directed to the Sponsor.&#xD;
&#xD;
          6. Participation in a clinical research study involving the administration of an&#xD;
             investigational or marketed drug or device within 30 days prior to the first dosing,&#xD;
             administration of a biological product in the context of a clinical research study&#xD;
             within 90 days prior to the first dosing, or concomitant participation in an&#xD;
             investigational study involving no drug or device administration.&#xD;
&#xD;
          7. Donation of blood 12 week prior to dosing.&#xD;
&#xD;
          8. Pregnant, or nursing females.&#xD;
&#xD;
          9. A history of substance abuse, psychiatric and psychological condition that, in the&#xD;
             judgment of the investigator, may interfere with the planned treatment and follow-up,&#xD;
             affect subject compliance or place the subject at high risk from treatment-related&#xD;
             complications&#xD;
&#xD;
         10. A history of severe allergic reaction to any HpHSA component.&#xD;
&#xD;
         11. A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a&#xD;
             QTcF interval &gt;450 milliseconds [ms])&#xD;
&#xD;
         12. History of or active obstructive disease in biliary tract, liver, kidney and spleen&#xD;
             defined by ultrasound.&#xD;
&#xD;
         13. Subjects who test positive for hepatitis B or C. (no matter carriers or active will be&#xD;
             excluded from the study&#xD;
&#xD;
         14. Subjects who test positive for Syphilis, Human immunodeficiency virus (HIV) positive&#xD;
             will also be excluded from the study.&#xD;
&#xD;
         15. Immunization with a live or attenuated vaccine is prohibited within 4 weeks prior to&#xD;
             study drug administration. Seasonal influenza vaccines for injection are generally&#xD;
             killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g.,&#xD;
             FluMist®) are live attenuated vaccines and are not allowed)&#xD;
&#xD;
         16. Positive Ig E and Ig G against rice at screening&#xD;
&#xD;
         17. History of significant alcohol abuse within one year prior to screening or regular use&#xD;
             of alcohol within six months prior to the screening visit (more than fourteen units of&#xD;
             alcohol per week [1 unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol])&#xD;
             or positive alcohol breath test at screening&#xD;
&#xD;
         18. History of significant drug abuse within one year prior to screening or use of soft&#xD;
             drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs&#xD;
             (such as cocaine, phencyclidine [PCP], crack, opioid derivatives including heroin, and&#xD;
             amphetamine derivatives) within 1 year prior to screening&#xD;
&#xD;
         19. Positive urine drug screen, cotinine test, or alcohol breath test at screening&#xD;
&#xD;
         20. Any reason which, in the opinion of the Qualified Investigator, would prevent the&#xD;
             subject from participating in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Nguyen, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>WCCT Global, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>WCCT Global, Inc</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 13, 2020</study_first_submitted>
  <study_first_submitted_qc>May 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <results_first_submitted>April 13, 2021</results_first_submitted>
  <results_first_submitted_qc>May 6, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 1, 2021</results_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OsrHSA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT04384523/Prot_SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 14, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT04384523/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo: Normal Saline (0.9% Sodium Chloride)</description>
        </group>
        <group group_id="P2">
          <title>OsrHSA 20 mg/kg IV</title>
          <description>OsrHSA 20 mg/kg IV: A single dose of OsrHSA 20 mg/kg IV infusion at a rate lower than 2 ml/min</description>
        </group>
        <group group_id="P3">
          <title>OsrHSA 40 mg/kg IV</title>
          <description>OsrHSA 40 mg/kg IV: A single dose of OsrHSA 40 mg/kg IV infusion at a rate lower than 2 ml/min</description>
        </group>
        <group group_id="P4">
          <title>OsrHSA 80 mg/kg IV</title>
          <description>OsrHSA 80 mg/kg IV: A single dose of OsrHSA 80 mg/kg IV infusion at a rate lower than 2 ml/min</description>
        </group>
        <group group_id="P5">
          <title>OsrHSA 140 mg/kg IV</title>
          <description>OsrHSA 140 mg/kg IV: A single dose of OsrHSA 140 mg/kg IV infusion at a rate lower than 2 ml/min</description>
        </group>
        <group group_id="P6">
          <title>OsrHSA 200 mg/kg IV</title>
          <description>OsrHSA 200 mg/kg IV: A single dose of OsrHSA 200 mg/kg IV infusion at a rate lower than 2 ml/min</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo: Normal Saline (0.9% Sodium Chloride)</description>
        </group>
        <group group_id="B2">
          <title>OsrHSA 20 mg/kg IV</title>
          <description>OsrHSA 20 mg/kg IV: A single dose of OsrHSA 20 mg/kg IV infusion at a rate lower than 2 ml/min</description>
        </group>
        <group group_id="B3">
          <title>OsrHSA 40 mg/kg IV</title>
          <description>OsrHSA 40 mg/kg IV: A single dose of OsrHSA 40 mg/kg IV infusion at a rate lower than 2 ml/min</description>
        </group>
        <group group_id="B4">
          <title>OsrHSA 80 mg/kg IV</title>
          <description>OsrHSA 80 mg/kg IV: A single dose of OsrHSA 80 mg/kg IV infusion at a rate lower than 2 ml/min</description>
        </group>
        <group group_id="B5">
          <title>OsrHSA 140 mg/kg IV</title>
          <description>OsrHSA 140 mg/kg IV: A single dose of OsrHSA 140 mg/kg IV infusion at a rate lower than 2 ml/min</description>
        </group>
        <group group_id="B6">
          <title>OsrHSA 200 mg/kg IV</title>
          <description>OsrHSA 200 mg/kg IV: A single dose of OsrHSA 200 mg/kg IV infusion at a rate lower than 2 ml/min</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="7"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.1" spread="8.82"/>
                    <measurement group_id="B2" value="34.2" spread="6.15"/>
                    <measurement group_id="B3" value="33.0" spread="7.13"/>
                    <measurement group_id="B4" value="35.3" spread="10.67"/>
                    <measurement group_id="B5" value="37.1" spread="9.49"/>
                    <measurement group_id="B6" value="36.0" spread="2.28"/>
                    <measurement group_id="B7" value="35.4" spread="7.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.0" lower_limit="22" upper_limit="50"/>
                    <measurement group_id="B2" value="34.5" lower_limit="26" upper_limit="44"/>
                    <measurement group_id="B3" value="33.5" lower_limit="25" upper_limit="41"/>
                    <measurement group_id="B4" value="34.0" lower_limit="22" upper_limit="54"/>
                    <measurement group_id="B5" value="37.0" lower_limit="22" upper_limit="50"/>
                    <measurement group_id="B6" value="35.5" lower_limit="34" upper_limit="40"/>
                    <measurement group_id="B7" value="35.0" lower_limit="22" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.8" spread="10.78"/>
                    <measurement group_id="B2" value="67.6" spread="13.51"/>
                    <measurement group_id="B3" value="68.2" spread="4.35"/>
                    <measurement group_id="B4" value="72.2" spread="10.36"/>
                    <measurement group_id="B5" value="76.0" spread="23.21"/>
                    <measurement group_id="B6" value="68.7" spread="17.56"/>
                    <measurement group_id="B7" value="68.6" spread="14.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kilograms</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.5" lower_limit="46.1" upper_limit="79.0"/>
                    <measurement group_id="B2" value="67.2" lower_limit="45.9" upper_limit="87.3"/>
                    <measurement group_id="B3" value="69.4" lower_limit="60.3" upper_limit="73.2"/>
                    <measurement group_id="B4" value="71.6" lower_limit="57.5" upper_limit="86.1"/>
                    <measurement group_id="B5" value="83" lower_limit="47.0" upper_limit="101.2"/>
                    <measurement group_id="B6" value="68.1" lower_limit="49.0" upper_limit="88.4"/>
                    <measurement group_id="B7" value="67.3" lower_limit="45.9" upper_limit="101.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>Centimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167.3" spread="8.59"/>
                    <measurement group_id="B2" value="165.7" spread="12.15"/>
                    <measurement group_id="B3" value="162.8" spread="8.47"/>
                    <measurement group_id="B4" value="173.4" spread="8.06"/>
                    <measurement group_id="B5" value="170.9" spread="12.22"/>
                    <measurement group_id="B6" value="168.3" spread="14.06"/>
                    <measurement group_id="B7" value="168.1" spread="10.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>Centimeter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167.5" lower_limit="155.6" upper_limit="178.3"/>
                    <measurement group_id="B2" value="169.0" lower_limit="148.1" upper_limit="179.9"/>
                    <measurement group_id="B3" value="161.4" lower_limit="155.2" upper_limit="177.6"/>
                    <measurement group_id="B4" value="171.8" lower_limit="163.6" upper_limit="187.3"/>
                    <measurement group_id="B5" value="171.1" lower_limit="155.4" upper_limit="186.3"/>
                    <measurement group_id="B6" value="165.8" lower_limit="154.0" upper_limit="192.9"/>
                    <measurement group_id="B7" value="169.1" lower_limit="148.1" upper_limit="192.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.0" spread="3.16"/>
                    <measurement group_id="B2" value="24.4" spread="2.91"/>
                    <measurement group_id="B3" value="25.8" spread="2.46"/>
                    <measurement group_id="B4" value="24.0" spread="2.50"/>
                    <measurement group_id="B5" value="25.4" spread="4.58"/>
                    <measurement group_id="B6" value="23.9" spread="3.32"/>
                    <measurement group_id="B7" value="24.1" spread="3.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.4" lower_limit="17.8" upper_limit="29.3"/>
                    <measurement group_id="B2" value="23.6" lower_limit="20.9" upper_limit="28.8"/>
                    <measurement group_id="B3" value="25.8" lower_limit="21.8" upper_limit="29.0"/>
                    <measurement group_id="B4" value="24.8" lower_limit="19.7" upper_limit="26.5"/>
                    <measurement group_id="B5" value="28.4" lower_limit="19.5" upper_limit="29.3"/>
                    <measurement group_id="B6" value="22.8" lower_limit="20.7" upper_limit="28.6"/>
                    <measurement group_id="B7" value="23.6" lower_limit="17.8" upper_limit="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Treatment-Emergent Adverse Events</title>
        <time_frame>from date of Informed Consent through Day 30 (Study Completion)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Normal Saline (0.9% Sodium Chloride)</description>
          </group>
          <group group_id="O2">
            <title>OsrHSA 20 mg/kg IV</title>
            <description>A single dose of OsrHSA 20 mg/kg IV</description>
          </group>
          <group group_id="O3">
            <title>OsrHSA 40 mg/kg IV</title>
            <description>A single dose of OsrHSA 40 mg/kg IV</description>
          </group>
          <group group_id="O4">
            <title>OsrHSA 80 mg/kg IV</title>
            <description>A single dose of OsrHSA 80 mg/kg IV</description>
          </group>
          <group group_id="O5">
            <title>OsrHSA 140 mg/kg IV</title>
            <description>A single dose of OsrHSA 140 mg/kg IV</description>
          </group>
          <group group_id="O6">
            <title>OsrHSA 200 mg/kg IV</title>
            <description>A single dose of OsrHSA 200 mg/kg IV</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Treatment-Emergent Adverse Events</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration [Cmax]</title>
        <time_frame>pre-dose, 0.5 hours after dose initiating, EOI (End of Infusion), and 0.5 hours, 4 hours, 12 hours, 24 hours (Day 2), 48 hours (Day 3), Day 5, Day 8, Day 15, Day 22, and Day 30 post End of Infusion.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With ADA Incident Events</title>
        <time_frame>pre-dose, Day 8, Day 15, Day 22, and Day 30 post End of Infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Normal Saline (0.9% Sodium Chloride)</description>
          </group>
          <group group_id="O2">
            <title>OsrHSA 20 mg/kg IV</title>
            <description>OsrHSA 20 mg/kg IV: A single dose of OsrHSA 20 mg/kg IV infusion at a rate lower than 2 ml/min</description>
          </group>
          <group group_id="O3">
            <title>OsrHSA 40 mg/kg IV</title>
            <description>OsrHSA 40 mg/kg IV: A single dose of OsrHSA 40 mg/kg IV infusion at a rate lower than 2 ml/min</description>
          </group>
          <group group_id="O4">
            <title>OsrHSA 80 mg/kg IV</title>
            <description>OsrHSA 80 mg/kg IV: A single dose of OsrHSA 80 mg/kg IV infusion at a rate lower than 2 ml/min</description>
          </group>
          <group group_id="O5">
            <title>OsrHSA 140 mg/kg IV</title>
            <description>OsrHSA 140 mg/kg IV: A single dose of OsrHSA 140 mg/kg IV infusion at a rate lower than 2 ml/min</description>
          </group>
          <group group_id="O6">
            <title>OsrHSA 200 mg/kg IV</title>
            <description>OsrHSA 200 mg/kg IV: A single dose of OsrHSA 200 mg/kg IV infusion at a rate lower than 2 ml/min</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With ADA Incident Events</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Screening to Day 30 +/- 2 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo: Normal Saline (0.9% Sodium Chloride)</description>
        </group>
        <group group_id="E2">
          <title>OsrHSA 20 mg/kg IV</title>
          <description>OsrHSA 20 mg/kg IV: A single dose of OsrHSA 20 mg/kg IV infusion at a rate lower than 2 ml/min</description>
        </group>
        <group group_id="E3">
          <title>OsrHSA 40 mg/kg IV</title>
          <description>OsrHSA 40 mg/kg IV: A single dose of OsrHSA 40 mg/kg IV infusion at a rate lower than 2 ml/min</description>
        </group>
        <group group_id="E4">
          <title>OsrHSA 80 mg/kg IV</title>
          <description>OsrHSA 80 mg/kg IV: A single dose of OsrHSA 80 mg/kg IV infusion at a rate lower than 2 ml/min</description>
        </group>
        <group group_id="E5">
          <title>OsrHSA 140 mg/kg IV</title>
          <description>OsrHSA 140 mg/kg IV: A single dose of OsrHSA 140 mg/kg IV infusion at a rate lower than 2 ml/min</description>
        </group>
        <group group_id="E6">
          <title>OsrHSA 200 mg/kg IV</title>
          <description>OsrHSA 200 mg/kg IV: A single dose of OsrHSA 200 mg/kg IV infusion at a rate lower than 2 ml/min</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Daichang Yang</name_or_title>
      <organization>Wuhan Healthgen Biotechnology Corp.</organization>
      <phone>18602708398</phone>
      <email>dyang@oryzogen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

